robatumumab
teratocarcinoma
seminoma
teprotumumab
malignin
tabalumab
taplitumomab
catumaxomab
ertumaxomab
oportuzumab monatox
mapatumumab
alacizumab
amivantamab
sibrotuzumab
caplacizumab
-mel-
pseudocapsule
oncotropic
tisotumab
testiculomata
tumorous
dalotuzumab
oncoimmunology
citatuzumab bogatox
iratumumab
-gov-
edrecolomab
pintumomab
immunoenzymatic
zalutumumab
immunochemiluminometric
-mab
neoplastic cell
agonistic monoclonal antibody
cergutuzumab
monoantibody
microlymphocytotoxicity
-mar-
durvalumab
histiocytoma
pritumumab
apolizumab
antimonoclonal
ensituximab
oncocytoma
malignancy
nimotuzumab
colosphere
nacolomab tafenatox
onco-